ÍøºìºÚÁÏ

Skip to main content

Clinical trials

Schedule appointment (352) 294-5400
Doctor holding a tablet and talking with a patient
  • Prosera

    The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.

    Investigator
    Ali Ataya
    Ages
    18 Years - 75 Years
    Sexes
    All
  • United therapeutics 301

    Study ROR-PH-301, ADVANCE OUTCOMES, is designed to assess the efficacy and safety of ralinepag when added to pulmonary arterial hypertension (PAH) standard of care or PAH-specific background therapy in subjects with World ÍøºìºÚÁÏ Organization (WHO)…

    Investigator
    Ali Ataya
    Ages
    18 Years - N/A
    Sexes
    All